FDA
-
-
-
-
-
-
-
Viking Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
-
-
-
-
-
-
-
Viking Therapeutics completes enrollment in VK2735 maintenance trial
-
-
-
-
-
-
-
BTIG Reiterates Buy Rating on Viking Therapeutic (VKTX)
-
-
-
-
-
-
-
Viking Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update
-
-
-
-
-
-
-
Viking Therapeutics Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Corporate Update
-
-
-
-
-
-
-
Viking Therapeutics to Highlight Clinical Data from VK2735 Obesity Program in Presentations at ObesityWeek® 2024
-
-
-
-
-
-
-
Viking Therapeutics (VKTX) Announces Results from Phase 1 Clinical Trial of Oral Tablet Formulation of VK2735
-
323,577 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

